複製鏈接
請複製以下鏈接發送給好友

郭興

(南京醫科大學神經生物學系教授)

鎖定
郭興,南京醫科大學特聘教授,博士生導師。國家優青獲得者,江蘇省特聘教授,江蘇省雙創團隊成員,現任神經生物學系副主任。主要研究方向:線粒體質量控制與神經退行性疾病。以第一或通訊作者在Journal of Clinical Investigation, EMBO molecular medicine, Nature communications,Signal Transduction and Targeted Therapy,Chemical Science等國際期刊發表多篇高水平論文。承擔國家自然科學基金優秀青年科學基金、國家自然科學基金面上項目(2項)、作為課題組長或研究骨幹參與科技部國家重點研發計劃2項。目前擔任中國生理學會青年委員會委員、中國生理學會幹細胞分會委員、江蘇省神經科學學會理事等。 [1] 
中文名
郭興
國    籍
中國
出生日期
1983年
教學職稱
教授
執業地點
南京醫科大學
研究方向
神經生物學
科研方向:
神經退行性疾病的分子機制及其干預治療 [2] 
近年承擔課題情況
1. 國家自然科學基金-優秀青年科學基金項目,亨廷頓病分子機制及其干預治療,82022021,120萬元,2020/10-2023/12,在研,主持。 [3] 
2. 國家自然科學基金面上項目,亨廷頓病中熱休克轉錄因子HSF1調控線粒體功能的研究,81971189,55萬元,2020/01-2023/12,在研,主持。 [4] 
3. 國家重點研發計劃,基於特定腦區類器官移植及評價體系研究,2021YFA1101802,625萬元,2021/12-2026/06,在研,子課題負責人。 [5] 
4. 國家重點研發計劃,家族性高膽固醇血癥發病新機制及其導致重要器官發育缺陷的研究,2019YFA0802700,104.4萬元,2019/12-2024/06,在研,研究骨幹。 [6] 
代表性論文:
1. Liu CY*, Fu ZX*, Wu SS*, Wang XS*, Zhang SR*, Chu C*, Hong Y, Wu WB, Chen SQ, Jiang YQ, Wu Y, Song YB, Liu Y#, Guo X#. Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington’s disease. EMBO Molecular Medicine. 2022 Jul 7;14(7):e15851. doi: 10.15252/emmm.202215851 . Epub 2022 Jun 7. PMID: 35670111 ; PMCID: PMC9260212 . [7] 
2. Lu KQ*, Hong Y*, Tao MD*, Shen LP*, Zheng ZL, Fang KH, Yuan F, Xu M, Wang C, Zhu DY, Guo X#, Liu Y#. Depressive patient-derived GABA interneurons reveal abnormal neural activity associated with HTR2C. EMBO Molecular Medicine. 2022 Nov 14;e16364. doi: 10.15252/emmm.202216364 . PMID: 36373384 . [8] 
3. Zhu WY*, Tao MD*, Hong Y, Wu SS, Chu C, Zheng ZL, Han X, Zhu Q, Xu M, Ewing AG#, Guo X#, Liu Y#. Dysfunction of vesicular storage in young-onset Parkinson’s patient-derived dopaminergic neurons and organoids revealed by single cell electrochemical cytometry. Chemical Science. 2022 May 11;13(21):6217-6223. doi: 10.1039/d2sc00809b . eCollection 2022 Jun 1. PMID: 35733907 ; PMCID: PMC9159080 . [9] 
4. Tang XY*, Wu SS*, Wang D, Chu C, Hong Y, Tao MD, Hu H, Xu M, Guo X#, Liu Y#. Human organoids in basic research and clinical applications. Signal Transduction and Targeted Therapy. 2022 May 24;7(1):168. doi: 10.1038/s41392-022-01024-9 . PMID: 35610212 ; PMCID: PMC9127490 . [10] 
5. Tang XY*, Xu L, Wang J, Hong Y, Wang Y, Zhu Q, Wang D, Zhang XY, Liu CY, Fang KH, Han X, Wang S, Wang X, Xu M, Bhattacharyya A, Guo X#, Lin M#, Liu Y#. DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome. Journal of Clinical Investigation. 2021 Jun 15;131(12): e135763. doi: 10.1172/JCI135763 . PMID: 33945512 ; PMCID: PMC8203468 . [11] 
6. Xu L*, Huo HQ, Lu KQ, Tang XY, Hong Y, Han X, Fu ZX, Fang KH, Xu M, Guo X#, Liu Y#. Abnormal mitochondria in Down syndrome iPSC-derived GABAergic interneurons and organoids. BBA-Molecular Basis of Disease. 2022 Jun 1;1868(6):166388. doi: 10.1016/j.bbadis.2022.166388 . Epub 2022 Mar 15. PMID: 35301086 . [12] 
7. Fu ZX*, Liu F*, Liu CY*, Jin BF, Jiang YQ, Tang ML, Qi X#, Guo X#. Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability. BBA-Molecular Basis of Disease. 2019 Jun 1;1865(6):1428-1435. doi: 10.1016/j.bbadis.2019.02.015 . Epub 2019 Feb 23. PMID: 30802639 ; PMCID: PMC6502650 . [13] 
8. Guo X*, Disatnik MH*, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X#. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. Journal of Clinical Investigation. 2013 Dec;123(12):5371-5388. doi: 10.1172/JCI70911 . Epub 2013 Nov 15. PMID: 24231356 ; PMCID: PMC3859413 . [14] 
9. Guo X*, Sun X, Hu D, Wang YJ, Fujioka H, Vyas R, Chakrapani S, Joshi AU, Luo Y, Mochly-Rosen D, Qi X#. VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease. Nature Communications. 2016 Aug 26;7:12646. doi: 10.1038/ncomms12646 . PMID: 27561680 ; PMCID: PMC5007466 . [15] 
參考資料
展開全部 收起